saprisartan potassium

Subscribe to Selected New Research on saprisartan potassium

8 relevant articles (0 outcomes, 2 trials/studies) found for this Bio-Agent

Description: structure given in first source

Also Known As:

1-((3-bromo-2-(2-(((trifluoromethyl)sulfonyl)amino)phenyl)-5-benzofuranyl)methyl)-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide; GR 138950; GR-138950; GR138950; GR138950C; sapri-sartan potassium

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Furans: 33

Benzofurans: 6

saprisartan potassium: 8

2-Ring Heterocyclic Compounds

Benzofurans: 6

saprisartan potassium: 8

Related Diseases

1.	Hypotension (Low Blood Pressure) 09/01/1996 - "9. The present study demonstrated that administration of either GR138950 or captopril to pregnant ewes effectively blocked the maternal RAS, and caused hypotension and a decrease in uterine blood flow" 07/01/2000 - "Overall, the magnitude of the hypotension induced by GR138950, and the concomitant rise in plasma renin, both correlated with the plasma cortisol concentration before GR138950 treatment" Get all the results and reference details, order at left...
2.	Hypertension (High Blood Pressure) 09/16/1994 - "Further studies are in progress to evaluate GR138950 in the treatment of hypertension." Get all the results and reference details, order at left...
3.	Tachycardia (Tachyarrhythmias) 11/01/1998 - "GR138950 caused a marked reduction in blood pressure associated with immediate tachycardia in conscious RALH rats" 12/01/1997 - "2. GR138950, enalapril or hydralazine caused marked reductions in blood pressure associated with immediate tachycardia in conscious RALH rats" 11/01/1998 - "The tachycardia caused by GR138950 was attenuated by atenolol and was abolished by combined pretreatment with atenolol and atropine methyl nitrate" 12/01/1997 - "The initial tachycardia caused by GR138950 or enalapril but not hydralazine was attenuated by L-NAME pretreatment" Get all the results and reference details, order at left...
4.	Right Ventricular Hypertrophy 11/01/1996 - "3. Rats treated intravenously with the AT1 antagonist, GR138950C, 1 mg kg-1 day-1 rather than saline alone during 7 days of exposure to hypoxia developed less pulmonary hypertension (pulmonary arterial pressure: 21.3 +/- 1.7 vs 28.3 +/- 1.1 mmHg; P < 0.05), right ventricular hypertrophy (right/left ventricle weight ratio: 0.35 +/- 0.01 vs 0.45 +/- 0.01; P < 0.05) and pulmonary artery remodelling (abundance of thick-walled pulmonary vessels: 9.6 +/- 1.4% vs 20.1 +/- 0.9%; P < 0.05)" Get all the results and reference details, order at left...
5.	Pulmonary Hypertension (Ayerza Syndrome) 11/01/1996 - "3. Rats treated intravenously with the AT1 antagonist, GR138950C, 1 mg kg-1 day-1 rather than saline alone during 7 days of exposure to hypoxia developed less pulmonary hypertension (pulmonary arterial pressure: 21.3 +/- 1.7 vs 28.3 +/- 1.1 mmHg; P < 0.05), right ventricular hypertrophy (right/left ventricle weight ratio: 0.35 +/- 0.01 vs 0.45 +/- 0.01; P < 0.05) and pulmonary artery remodelling (abundance of thick-walled pulmonary vessels: 9.6 +/- 1.4% vs 20.1 +/- 0.9%; P < 0.05)" Get all the results and reference details, order at left...
8 Diseases and 8 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Captopril (Capoten)
2.	Losartan (Cozaar)
3.	NG-Nitroarginine Methyl Ester (L-NAME)
4.	Renin
5.	Hydrocortisone (Cortisol)
6.	Hydralazine (Apresoline)
7.	Enalapril
8.	Atropine (Hyoscyamine)
9.	Atenolol (Tenormin)
10.	methyl nitrate
10 Drugs and Important Bio-Agents and 5 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>